Navigation Links
Cardiogenesis Enrolls First Two Patients in Its Feasibility Study of the PHOENIX® Combination Delivery System
Date:10/12/2010

IRVINE, Calif., Oct. 12 /PRNewswire/ -- Cardiogenesis Corporation (OTCQB: CGCP), a leading developer of surgical products used in the treatment of diffuse coronary artery disease, reported the enrollment of the first two patients in its PHOENIX Feasibility Study.  Dr. Guillermo Reyes at La Princesa Hospital, Madrid, Spain performed the procedures utilizing the company's proprietary PHOENIX System that combines the intramyocardial delivery of stem cells with transmyocardial revascularization (TMR).

"Myocardial stimulation via TMR has been proven to reduce angina for the majority of treated patients.  The synergy of the injection of autologous stem cells may provide greater angina reduction, and improve cardiac function in patients with diffuse disease who are not candidates for surgical bypass or intervention," commented Dr. Reyes.  "Survival rates have significantly improved for persons with coronary artery disease; however as this population lives longer they can outlive the effectiveness of their prior therapy.  Clinicians are faced with an expanding population of symptomatic patients with no option for conventional treatments.  Stem cell therapy with the Cardiogenesis technology has great promise as a solution for this growing clinical problem."

The two procedures were performed during an investigator meeting in Madrid, Spain on October 7-8.  Leading researchers at five medical centers from France, India, Italy, Russia, and Spain will participate in the study.  The company plans to begin clinical cases at those centers in the upcoming weeks.

"This is a significant milestone.  We will provide the early results of this feasibility study along with the pre-clinical testing being conducted at the Stem Cell Center of the Texas Heart Institute, to support our request to begin a multi-center IDE pivotal trial in the U.S. for the PHOENIX System," said Cardiogenesis Executive Chairman Paul McCormick.  "We believe the injection of stem cells combined with the pretreatment of TMR system can prove to be an effective therapy for an expanding population of patients with no options and will provide a proprietary growth opportunity for our company."

About Cardiogenesis Corporation

Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that treat severe angina.  Our market leading holmium:YAG laser system and single use fiber-optic delivery systems are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR).

For more information on Cardiogenesis and its products, please visit our website at www.cardiogenesis.com.

Safe Harbor Statement

This press release contains forward-looking statements, including, without limitation, with respect to the Company's expectation to begin a U.S. clinical trial of the Company's PHOENIX™ Combination Delivery System.  Any forward-looking statements in this news release are subject to numerous risks and uncertainties, many of which are outside the Company's control, that could cause actual results to differ materially.  Factors that could affect the accuracy of these forward-looking statements include, but are not limited to: any inability by the Company to sustain profitable operations or obtain additional financing on favorable terms if and when needed; any failure to obtain required regulatory approvals; failure of the medical community to expand its acceptance of TMR procedures; possible adverse governmental rulings or regulations, including any FDA regulations or rulings; the Company's ability to comply with international and domestic regulatory requirements; possible adverse Medicare or other third-party reimbursement policies or adverse changes in those policies; any inability by the Company to ship product on a timely basis; the Company's ability to manage its growth; the effects of recent disruptions in global credit and equity markets and other adverse economic developments that could adversely affect the market for our products or our ability to raise needed financing; actions by our competitors; and the Company's ability to protect its intellectual property.  Other factors that could cause Cardiogenesis' actual results to differ materially are discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2009 and the Company's other filings with the Securities and Exchange Commission.  The Company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.


'/>"/>
SOURCE Cardiogenesis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardiogenesis Executive Chairman Paul J. McCormick Updates Commercial and Regulatory Progress in Interview With Wall Street Reporter, Available Online
2. Cardiogenesis Corporation to Report 2010 Second Quarter Results on August 4th
3. Cardiogenesis (CGCP) Listing Upgraded to New OTCQB(TM) Market for All U.S. Registered and Reporting OTC Securities
4. Cardiogenesis Corporation to Present at Noble Financial - ONTRACK 2010
5. Cardiogenesis Reports Third Quarter 2009 Results
6. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
7. Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
8. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
9. BHR Pharma Enrolls First Patient in Phase 3 SyNAPSe Traumatic Brain Injury Trial
10. Crux Biomedical Enrolls First Patient in Its Retrieve 2 U.S. Pivotal Trial
11. Ophthotech Enrolls Its First Patient in a Randomized, Controlled Phase II Study of E10030 in Macular Degeneration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)...  Glenmark Pharmaceuticals, a global pharmaceutical company, today ... fixed-dose combination of mometasone furoate (25 mcg) and ... nasal spray being studied for the treatment of ... recently completed Phase 3 trial assessing the efficacy ... mometasone, olopatadine or placebo. "We continue ...
(Date:3/29/2017)... New York , March 29, 2017 /PRNewswire/ ... recently published a report, which provides an exhaustive ... to the study, nearly 242 companies are functional ... fragmented and competitive. With the leading companies, such ... Purdue Pharma LP, focusing aggressively on various marketing ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "Global ... ... market to grow at a CAGR of 2.87% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Hamlin Dental Group, multi-location dental ... offering laser dental treatments. Dental lasers are safe and effective options, and can be ... and can improve the overall quality of care. , Dr. Hamid Reza of Hamlin ...
(Date:3/29/2017)... ... ... AvePoint , the Microsoft Cloud expert, is pleased to announce the official ... Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating with a ribbon-cutting ceremony on ... of Richmond Levar M. Stoney. , Founded in 2001, AvePoint employs more than 1,400 ...
(Date:3/28/2017)... ... March 28, 2017 , ... For many women, getting birth control isn’t as easy ... meaning they either don’t have access to a health care facility or a pharmacy within ... regions of the United States or for many who are faced with health or personal ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... state legislatures and Congress to protect parental rights and civil liberties, and to ... in America. , The demonstration coincides with a press conference taking place Friday ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... software and services, is proud to announce it has joined the National Association ... representing the interests of chronically ill, disabled, and dying Americans of all ages ...
Breaking Medicine News(10 mins):